Anne Li 6/9/17
|
A certain group of genetic faults could be used to help predict if immunotherapy will work in cancer patients, according to a new US study. The research from John Hopkins University in Baltimore found that a significant number of patients whose tumours had defects in genes involved in DNA repair responded to the immunotherapy drug, pembrolizumab (Keytruda). The researchers looked at the genes in patients’ tumours. They found that the patients who responded to this treatment all had cancers with defects in a set of genes called mismatch repair genes.
See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-06-09-certain-genetic-faults-could-help-predict-success-of-immunotherapy |